A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients With Rheumatoid Arthritis

Rheumatology and Therapy

doi 10.1007/s40744-019-00186-3

Full Text

Abstract

Available in

Date

December 12, 2019

Authors

Publisher

Springer Science and Business Media LLC

Related search

Comparative Clinical Efficacy and Safety of the Proposed Biosimilar ABP 710 With Infliximab Reference Product in Patients With Rheumatoid Arthritis

Arthritis Research & Therapy

2020

English

Switch From Reference Etanercept to SDZ ETN, an Etanercept Biosimilar, Does Not Impact Efficacy, Safety, and Immunogenicity of Etanercept in Patients With Moderate-To-Severe Rheumatoid Arthritis: 48-Week Results From the Phase III, Randomized, Double-Blind EQUIRA Study

Arthritis Research & Therapy

2019

English

OP0021 Efficacy and Safety Results of a Phase Iii Study Comparing Fkb327, an Adalimumab Biosimilar, With the Adalimumab Reference Product in Patients With Active Rheumatoid Arthritis

2017

English

A Comparative Study to Assess the Efficacy of Permethrin (Topical) and Benzyl Benzoate (Topical) for the Treatment of Scabies Patients

International Journal of Research in Pharmaceutical Sciences

English

Azilsartan Improves the Effects of Etanercept in Patients With Active Rheumatoid Arthritis: A Pilot Study

Therapeutics and Clinical Risk Management

2018

English

The Efficacy and Safety of Abatacept in Rheumatoid Arthritis

Therapeutic Advances in Musculoskeletal Disease

English

A Phase III Randomized Study to Evaluate the Efficacy and Safety of CT-P13 Compared With Reference Infliximab in Patients With Active Rheumatoid Arthritis: 54-Week Results From the PLANETRA Study

Arthritis Research & Therapy

2016

English

Fri0087 Efficacy, Safety, and Immunogenicity Results of the Switch From Reference Adalimumab (Refadl) to Sandoz Biosimilar Adalimumab (Gp2017, SDZ-Adl) From Admyra Phase 3 Study in Patients With Moderate-To-Severe Rheumatoid Arthritis (Ra)

2019

English

Patients’ Views About Treatment With Combination Therapy for Rheumatoid Arthritis: A Comparative Qualitative Study

BMC Musculoskeletal Disorders

English

Amanote Research

A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients With Rheumatoid Arthritis

Rheumatology and Therapy

Full Text

Abstract

Date

Authors

Publisher

Related search

Comparative Clinical Efficacy and Safety of the Proposed Biosimilar ABP 710 With Infliximab Reference Product in Patients With Rheumatoid Arthritis

Switch From Reference Etanercept to SDZ ETN, an Etanercept Biosimilar, Does Not Impact Efficacy, Safety, and Immunogenicity of Etanercept in Patients With Moderate-To-Severe Rheumatoid Arthritis: 48-Week Results From the Phase III, Randomized, Double-Blind EQUIRA Study

OP0021 Efficacy and Safety Results of a Phase Iii Study Comparing Fkb327, an Adalimumab Biosimilar, With the Adalimumab Reference Product in Patients With Active Rheumatoid Arthritis

A Comparative Study to Assess the Efficacy of Permethrin (Topical) and Benzyl Benzoate (Topical) for the Treatment of Scabies Patients

Azilsartan Improves the Effects of Etanercept in Patients With Active Rheumatoid Arthritis: A Pilot Study

The Efficacy and Safety of Abatacept in Rheumatoid Arthritis

A Phase III Randomized Study to Evaluate the Efficacy and Safety of CT-P13 Compared With Reference Infliximab in Patients With Active Rheumatoid Arthritis: 54-Week Results From the PLANETRA Study

Fri0087 Efficacy, Safety, and Immunogenicity Results of the Switch From Reference Adalimumab (Refadl) to Sandoz Biosimilar Adalimumab (Gp2017, SDZ-Adl) From Admyra Phase 3 Study in Patients With Moderate-To-Severe Rheumatoid Arthritis (Ra)

Patients’ Views About Treatment With Combination Therapy for Rheumatoid Arthritis: A Comparative Qualitative Study